293 related articles for article (PubMed ID: 22821802)
1. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
2. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
3. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
5. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.
Holmes L; Chan W; Jiang Z; Du XL
Prostate Cancer Prostatic Dis; 2007; 10(4):388-95. PubMed ID: 17486111
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
9. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
[TBL] [Abstract][Full Text] [Related]
10. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
11. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
[TBL] [Abstract][Full Text] [Related]
12. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
[TBL] [Abstract][Full Text] [Related]
13. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
[TBL] [Abstract][Full Text] [Related]
14. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
18. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
[TBL] [Abstract][Full Text] [Related]
19. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
Berthelet E; Pickles T; Lee KW; Liu M; Truong PT;
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):781-7. PubMed ID: 16199312
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
